Invitris

Application YC di Invitris

Winter 2023Active

Invitris ha partecipato a Y Combinator nel batch Winter 2023 come azienda Healthcare. Sotto: cosa fa l'azienda, chi l'ha fondata e la sua application a YC, ricostruita domanda per domanda nel form reale di YC.

Batch YC
Winter 2023
Settore
HealthcareDrug Discovery and Delivery
Dimensione team
6
Stato
Active
Lanciata
2023

Founder

  • Patrick Grossmann
    Patrick GrossmannFounder
  • Kilian Vogele
    Kilian VogeleFounder

Cosa fa Invitris

Invitris radically simplifies how we create novel biological drugs. Our patent-pending technology platform turns DNA into synthetic proteins and was recently featured in the Science magazine. It makes creating new drugs >10,000x more efficient at <100x lower costs of material. Our killer application is enabling the newest generation of synthetic bacteriophages to combat antibiotic-resistant infections, which are threatening to cause more deaths than all cancers combined.

Application YC di Invitris, ricostruita

Domanda per Y Combinator

Invitris, batch Winter 2023. Le vere domande del form, risposte da dati pubblici.

  1. Founders2
  2. Company7
  3. Progress7
  4. Idea4
  5. Equity3
  6. Curious2
  7. Batch Preference1

Company

Company name

Invitris

Describe what your company does in 50 characters or less.

Creating new protein-based drugs at scale

What is your company going to make? Please describe your product and what it does or will do.

We're building a platform that turns DNA into synthetic proteins to create new biological drugs. It makes designing and producing proteins more than 10,000 times more efficient and cuts material costs by over 100 times compared to traditional methods. Our first focus is synthetic bacteriophages to fight antibiotic-resistant infections, which are causing more deaths than all cancers combined.

Where do you live now, and where would the company be based after YC?

We live and operate in Munich, Bavaria, Germany. After YC, we would continue to base the company here.

Explain your decision regarding location.

We're based in Munich because that's where we have access to our core team and labs, and Germany has a strong biotech ecosystem that supports our work.

21 risposte in più nell'application completa

Founders, Progress, Idea, Equity, Curious, Batch Preference sono nella versione completa. Crea un account gratuito per aprirla in YC Insights, accanto a ogni altro batch YC.

Domande Frequenti

Questa è l'application YC reale di Invitris?

No. Y Combinator mantiene private le application inviate. Questa è una ricostruzione: le domande del form YC reale, a cui si è risposto usando i dati pubblici di Invitris (note di lancio, background dei founder, descrizione del prodotto). Mostra come un'azienda come Invitris si presenterebbe a YC, non il testo che hanno inviato.

A quale batch YC apparteneva Invitris?

Invitris apparteneva al batch Winter 2023 di Y Combinator.

Chi ha fondato Invitris?

Invitris è stato fondato da Patrick Grossmann, Kilian Vogele.

Cosa fa Invitris?

Creating new protein-based drugs at scale

Come leggo la ricostruzione completa della application?

Crea un account Round Funded gratuito. La versione completa di 26 risposte della application di Invitris, e di ogni altro batch YC, è in YC Insights.

Più startup YC come Invitris